AbbVie and Eisai Announce an approval for additional indication of HUMIRA
A fully Human Anti-TNFalpha Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the
Published on Sat, 28 Nov 2020 14:24:17 +0000 and brought to you by Apptigent PowerTools